Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites
2015
Purpose
Bendamustine is a unique alkylating agent indicated for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B cell non-Hodgkin’s lymphoma. Despite the extensive experience with bendamustine, its pharmacokinetic profile has only recently been described. This overview summarizes the pharmacokinetics, pharmacokinetic/pharmacodynamic relationships, and drug–drug interactions of bendamustine in adult and pediatric patients with hematologic malignancies.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
56
References
19
Citations
NaN
KQI